These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36092144)

  • 1. Recent applications of covalent chemistries in protein-protein interaction inhibitors.
    Chan AM; Goodis CC; Pommier EG; Fletcher S
    RSC Med Chem; 2022 Aug; 13(8):921-928. PubMed ID: 36092144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophilic warheads in covalent drug discovery: an overview.
    Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
    Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase.
    Awoonor-Williams E; Rowley CN
    J Chem Inf Model; 2021 Oct; 61(10):5234-5242. PubMed ID: 34590480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Suppression of a Protein-Protein Interaction in Cells Using Small-Molecule Covalent Inhibitors Based on an
    Ueda T; Tamura T; Kawano M; Shiono K; Hobor F; Wilson AJ; Hamachi I
    J Am Chem Soc; 2021 Mar; 143(12):4766-4774. PubMed ID: 33733756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in covalent warheads for in vivo targeting of endogenous proteins.
    Shindo N; Ojida A
    Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CovPDB: a high-resolution coverage of the covalent protein-ligand interactome.
    Gao M; Moumbock AFA; Qaseem A; Xu Q; Günther S
    Nucleic Acids Res; 2022 Jan; 50(D1):D445-D450. PubMed ID: 34581813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
    Ábrányi-Balogh P; Petri L; Imre T; Szijj P; Scarpino A; Hrast M; Mitrović A; Fonovič UP; Németh K; Barreteau H; Roper DI; Horváti K; Ferenczy GG; Kos J; Ilaš J; Gobec S; Keserű GM
    Eur J Med Chem; 2018 Dec; 160():94-107. PubMed ID: 30321804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding Mode Prediction and Virtual Screening Applications by Covalent Docking.
    Scarpino A; Ferenczy GG; Keserű GM
    Methods Mol Biol; 2021; 2266():73-88. PubMed ID: 33759121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent docking in CDOCKER.
    Wu Y; Brooks Iii CL
    J Comput Aided Mol Des; 2022 Aug; 36(8):563-574. PubMed ID: 35984589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.
    Yang J; Tabuchi Y; Katsuki R; Taki M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies.
    Lucero B; Francisco KR; Liu LJ; Caffrey CR; Ballatore C
    Trends Pharmacol Sci; 2023 Jul; 44(7):474-488. PubMed ID: 37263826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases.
    Petri L; Egyed A; Bajusz D; Imre T; Hetényi A; Martinek T; Ábrányi-Balogh P; Keserű GM
    Eur J Med Chem; 2020 Dec; 207():112836. PubMed ID: 32971426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Covalent Inhibitors for Drug Design.
    Baillie TA
    Angew Chem Int Ed Engl; 2016 Oct; 55(43):13408-13421. PubMed ID: 27539547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitriles: an attractive approach to the development of covalent inhibitors.
    Bonatto V; Lameiro RF; Rocho FR; Lameira J; Leitão A; Montanari CA
    RSC Med Chem; 2023 Feb; 14(2):201-217. PubMed ID: 36846367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent Docking in Drug Discovery: Scope and Limitations.
    Scarpino A; Ferenczy GG; Keserű GM
    Curr Pharm Des; 2020; 26(44):5684-5699. PubMed ID: 33155894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.
    Schwartz PA; Kuzmic P; Solowiej J; Bergqvist S; Bolanos B; Almaden C; Nagata A; Ryan K; Feng J; Dalvie D; Kath JC; Xu M; Wani R; Murray BW
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):173-8. PubMed ID: 24347635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets.
    Lee J; Park SB
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors.
    Li B; Rong D; Wang Y
    Curr Top Med Chem; 2019; 19(21):1872-1876. PubMed ID: 31696799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors.
    Mader L; Watt SKI; Iyer HR; Nguyen L; Kaur H; Keillor JW
    RSC Med Chem; 2023 Feb; 14(2):277-298. PubMed ID: 36846370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.